Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE).
Adolescent
Adult
Aged
Aged, 80 and over
Anticonvulsants
/ therapeutic use
Austria
Benzodiazepines
/ therapeutic use
Dose-Response Relationship, Drug
Female
Germany
Guideline Adherence
Humans
Levetiracetam
/ therapeutic use
Male
Middle Aged
Multivariate Analysis
Practice Guidelines as Topic
Prognosis
Proportional Hazards Models
Prospective Studies
Registries
Status Epilepticus
/ drug therapy
Switzerland
Time Factors
Treatment Outcome
Young Adult
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
07
09
2018
revised:
15
01
2019
accepted:
15
01
2019
pubmed:
21
1
2019
medline:
14
1
2020
entrez:
21
1
2019
Statut:
ppublish
Résumé
To investigate the initial termination rate of status epilepticus (SE) in a large observational study and explore associated variables. Data of adults treated for SE were collected prospectively in centers in Germany, Austria, and Switzerland, during 4.5 years. Incident episodes of 1,049 patients were analyzed using uni- and multivariate statistics to determine factors predicting cessation of SE within 1 hour (for generalized convulsive SE [GCSE]) and 12 hours (for non-GCSE) of initiating treatment. Median age at SE onset was 70 years; most frequent etiologies were remote (32%) and acute (31%). GCSE was documented in 43%. Median latency between SE onset and first treatment was 30 minutes in GCSE and 150 minutes in non-GCSE. The first intravenous compound was a benzodiazepine in 86% in GCSE and 73% in non-GCSE. Bolus doses of the first treatment step were lower than recommended by current guidelines in 76% of GCSE patients and 78% of non-GCSE patients. In 319 GCSE patients (70%), SE was ongoing 1 hour after initiating treatment and in 342 non-GCSE patients (58%) 12 hours after initiating treatment. Multivariate Cox regression demonstrated that use of benzodiazepines as first treatment step and a higher cumulative dose of anticonvulsants within the first period of treatment were associated with shorter time to cessation of SE for both groups. In clinical practice, treatment guidelines were not followed in a substantial proportion of patients. This underdosing correlated with lack of cessation of SE. Our data suggest that sufficiently dosed benzodiazepines should be used as a first treatment step. ANN NEUROL 2019;85:421-432.
Substances chimiques
Anticonvulsants
0
Benzodiazepines
12794-10-4
Levetiracetam
44YRR34555
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-432Informations de copyright
© 2019 American Neurological Association.